What does a Controlled Attenuation Parameter of 323 dB/m indicate and how should it be managed?

CAP of 323 dB/m Indicates Severe Hepatic Steatosis (S3)

A CAP value of 323 dB/m indicates severe hepatic steatosis (S3, affecting >30% of hepatocytes) and requires comprehensive metabolic risk assessment and lifestyle intervention as first-line management.

Interpretation of CAP 323 dB/m

Based on the most recent 2024 EASL-EASD-EASO guidelines, your CAP value falls into the severe steatosis category 1:

• S1 (mild steatosis): 248 dB/m threshold
• S2 (moderate steatosis): 268 dB/m threshold
• S3 (severe steatosis): 280 dB/m threshold

Your value of 323 dB/m clearly exceeds the S3 threshold of 280 dB/m, placing you in the severe steatosis category 1. Multiple validation studies confirm this interpretation, with research showing median CAP values for S3 steatosis ranging from 322-329 dB/m 2, 3.

Important Caveat About Accuracy

CAP accuracy is reduced in obesity (BMI ≥30 kg/m²). If you have a BMI ≥30, the cut-off values may need to be adjusted upward by approximately 28-31 dB/m 4. However, even accounting for this adjustment, your value of 323 dB/m still indicates at least moderate-to-severe steatosis 5.

Clinical Significance and Risk Stratification

Severe hepatic steatosis at this level carries important prognostic implications:

• Predicts future type 2 diabetes, cardiovascular events, and hypertension 6
• Increased risk of fibrosis progression if steatohepatitis (NASH/MASH) is present 6
• Requires assessment of fibrosis stage to determine overall liver-related risk

Next Critical Step: Assess for Fibrosis

You must undergo fibrosis assessment using non-invasive tools 1. The guidelines strongly recommend:

1. Calculate FIB-4 score (age, AST, ALT, platelet count):

   • FIB-4 <1.3: Low risk of advanced fibrosis
   • FIB-4 >2.67: High risk of advanced fibrosis
   • Intermediate values require further testing

2. Obtain liver stiffness measurement (LSM) via the same FibroScan device:

   • LSM <8 kPa: Unlikely advanced fibrosis
   • LSM ≥12 kPa: Likely advanced fibrosis (F3)
   • Consider referral to hepatology if LSM ≥8 kPa 1

Management Algorithm

1. Mandatory Laboratory and Clinical Assessment 1

Obtain the following at initial diagnosis:

• Complete metabolic panel: AST, ALT, alkaline phosphatase, bilirubin, albumin
• Platelet count (for FIB-4 calculation)
• Lipid panel: Total cholesterol, LDL, HDL, triglycerides
• Glucose metabolism: Fasting glucose, HbA1c, consider HOMA-IR
• Kidney function: Creatinine, eGFR
• Screen for metabolic comorbidities:
  • Type 2 diabetes or prediabetes
  • Hypertension
  • Dyslipidemia
  • Sleep apnea (if symptoms present)
  • Polycystic ovary syndrome (in women)

2. Cardiovascular Risk Assessment 1

Assess 10-year cardiovascular risk using validated calculators (ASCVD risk score). Patients with MASLD have elevated cardiovascular mortality risk independent of traditional risk factors.

3. First-Line Treatment: Lifestyle Modification

Weight loss of 7-10% is the primary therapeutic target for reducing steatosis and improving metabolic parameters:

• Dietary intervention: Mediterranean diet or caloric restriction (500-1000 kcal/day deficit)
• Physical activity: 150-200 minutes/week of moderate-intensity aerobic exercise plus resistance training
• Avoid alcohol: Complete abstinence or minimal consumption (<20g/day for women, <30g/day for men)

4. Treat Metabolic Comorbidities Aggressively

• Diabetes: Optimize glycemic control (target HbA1c <7%)
• Dyslipidemia: Statin therapy if indicated by cardiovascular risk
• Hypertension: Target BP <130/80 mmHg

5. Follow-Up Monitoring

• Repeat CAP and LSM in 12 months to assess response to lifestyle intervention 7
• Monitor liver enzymes every 3-6 months
• Annual reassessment of metabolic parameters

6. Consider Hepatology Referral If:

• LSM ≥8 kPa (suggesting significant fibrosis)
• FIB-4 >2.67
• Persistently elevated ALT despite lifestyle modification
• Presence of cirrhosis complications
• Consideration for pharmacotherapy

Common Pitfalls to Avoid

1. Don't ignore this finding: CAP 323 dB/m represents significant liver fat accumulation requiring intervention
2. Don't assume absence of fibrosis: Steatosis and fibrosis are assessed separately; you need LSM or FIB-4
3. Don't delay metabolic screening: Extrahepatic complications (diabetes, cardiovascular disease) are the leading causes of mortality in MASLD 1
4. Don't rely on ALT alone: Normal ALT does not exclude significant liver disease in MASLD

Prognosis and Monitoring

Research demonstrates that one dB/m change in CAP corresponds to approximately 0.039% change in liver fat by MRI 7. Your baseline CAP of 323 dB/m provides a quantitative target for monitoring treatment response. Successful lifestyle intervention should reduce CAP by at least 20-30 dB/m over 12 months, corresponding to meaningful reduction in liver fat content.